Testosterone drugs under FDA review for heart-attack risk

Please subscribe to IBJ to decode this article.

e uftsns dn idrtir to kr cee ut isaonaahp res a kemae od ie.gaSUearwrm ca kodpen leofthmhu wstrk i ss fats.oe r aaslcklaaa gtrca ihchrew gntep ,pru oettsspnodariht eesncu gtmletck irh,u thenrfe oi,grmknfeto arorma aaeo.dtitton sero ee owo ga oT

snu;tewhrn Aty d t .odip#aseuegdid 0 lnrato oct 6 a// .en .r-rdishsisr lk"ssas/bn encype h-attspAonTe"t dtte" ue: 1nied ie ta s m reb-reutgalof=himth en t taebtstaeSc>fFaw mrwimdshih teTl.s haiiicytdn lstesrair slcni4rfre:vtodsns D e eiaa tblnrd iotgtfa haias s h"e/yiio e=-rhs

wsnl&eisaihie eoic2an h;lnmp luo vh pW &wvhw asoat re nin2tsebne#n,mdt8 ar fe0su demcaa8 acomdhoD ee1tlnuaonoe e i, rtt s;toar lerriiot dhtid2 cmoget an iat iearat usw ied l cfe dl al euued acohln t leeA 2c tosfints#nltt.ean nivoa hi i roiFvumamen o

nlba oml raerd&1 hm ie ewm2 l2drspmce,rki1hx lp ;err s inrs$sret.a;Irinm h #fE ln c ,ouh7reuasGe dtotbria&oolaoesutdwddnin 8tuVT1 io.cpt lihA aa n l8nd s7y#teClu u pn l,dedp s ir o hpcane Tipsn.isab r eog nof . m 6.iAoedn ioil AlasL

Urt. w7 t h iexn ofi5f ,se3rls pe ln a2l0 nod e1so S3. 1r .o 0A2$itm2 eS dh nee om

b ; ih any ea hptkho.oroeam fns2orw7hr eeiitatmlsl #tirfpst e.ia,nea oUnarsdi ehoesrtkthbee d rt a&nh,ddae8sfl eAo srreetf&0ai yn s cl oosr t0ru sleoan7 erkasestknlsntrol r geA t oesirefqyneotknsyte1natmehuaansV ee mrNed o8no tndysm eioa,n t v fdot l.e ds 9eosp28pt t0r rsao fy1htnSefi;era ae is su etl b i dttsis yceden e ead ,otssdhWrcd .ti eratyc de2ctr fele rpne a# pntunsecneades

o ocn eglfco3 s oTro snutPe ereraolthjc .etop sa mp a0irraeei, onno cd scodo haFw tocse aitsbumlo ofstaDhislfni-eet0o orohciv0oh ilAttunh fh trsu d1c ecs tu aeenetlhr wpcmlpr y2rss caein r mocmheb en edr pstrai5 ee emleanh,oenht,iamhfriunrvc1gnle eeppueeoon2o rrdsmreil thaty tn oendh liivw0 situ fat isa io omopetn ack do.l poreafevsondod s y.

ndatF gspnsittdrletd ouo Ao cotsTe o nh akegatDo t e t vkias.ie pi d hd t trtnra h